

**Figure 1 Flow diagram of the selection process of literature.**



**Figure 2 Risk of bias graph for all included studies.**



**Figure 3 Risk of bias summary for all included study.**

**a**



**b**

****

**c**

****

**d**

****

**Figure 4 Network evidence plots of efficacy indicators.**

Change in the Mini Mental State Examination (MMSE) from baseline (**a**); Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) from baseline (**b**); Change in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) from baseline (**c**); Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) from baseline (**d**).

**a**

****

**b**

****

**c**



**d**



**Figure 5 Network evidence plots of safety indicators.**

adverse events (AE) (**a**); serious adverse events (SAE) (**a**); fall (**a**); urinary tract infection (**a**); infusion-related reaction (**b**); amyloid-related imaging abnormalities with edema or effusions (ARIA-E) (**c**); amyloid-related imaging abnormalities with hemosiderin deposits (ARIA-H) (**d**).

**a**



**b**

****

**c**

****

**d**

****

**Figure 6 Funnel plots of efficacy indicators.**

Change in the Mini Mental State Examination (MMSE) from baseline (**a**); Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) from baseline (**b**); Change in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) from baseline (**c**); Change in Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) from baseline (**d**).

**a**

****

**b**

****

**c**

****

**d**

****

**e**

****

**f**

****

**g**

****

**Figure 7 Funnel plots of safety indicators.**

adverse events (AE) (**a**); serious adverse events (SAE) (**b**); fall (**c**); urinary tract infection (**d**); infusion-related reaction (**e**); amyloid-related imaging abnormalities with edema or effusions (ARIA-E) (**f**); amyloid-related imaging abnormalities with hemosiderin deposits (ARIA-H) (**g**).